Rinri Therapeutics

Company

University of Sheffield spinout. Developer of Rincell-1, a cell therapy using lab-grown otic neural progenitor cells; its first MHRA-approved human trial began enrollment in May 2026, targeting neural hearing loss rather than tinnitus directly.